文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌根治性放疗急性与晚期不良事件:随机对照试验中临床医生与患者毒性报告的系统综述

Acute and Late Adverse Events Associated With Radical Radiation Therapy Prostate Cancer Treatment: A Systematic Review of Clinician and Patient Toxicity Reporting in Randomized Controlled Trials.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2016-11-18

该系统综述检索MEDLINE、EMBASE与Cochrane数据库(2014年4月至8月),纳入21篇文章、15项随机对照试验共9040例非转移性前列腺癌根治性放疗患者,评估急性与晚期不良事件的报告工具与方法学质量。结果显示急性不良事件仅由临床医生报告工具记录,晚期不良事件有48%的文章采用患者报告结局(PRO)工具,但无公认的首选工具。作者认为患者报告在放疗试验中代表性不足,建议在治疗前、中、后统一纳入PRO评估。

要点

  • 急性不良事件仅用临床医生报告工具记录,如RTOG和CTCAE。
  • 晚期不良事件有48%的文章使用PRO工具,但无明确首选工具。
  • 建议放疗前、中、后纳入PRO以全面捕捉患者体验。

核心结论

  • 患者对急性和晚期不良事件的报告在放疗试验中代表性不足,建议致力于形成放疗相关不良事件PRO评估的一致方法。

研究设计与样本

  • 系统综述,按PRISMA声明检索MEDLINE、EMBASE和Cochrane数据库(2014年4月至8月),筛选1149条记录,最终纳入21篇文章。
  • 纳入15项随机对照试验、共9040例非转移性前列腺癌根治性放疗患者,依据PRO CONSORT指南和Cochrane偏倚风险工具评价。

主要发现

  • 急性不良事件(<3个月)仅使用临床医生报告工具,如RTOG和CTCAE。
  • 晚期临床医生报告使用LENT-SOMA量表和RTOG,常附加条目以覆盖性功能和肛门直肠症状。
  • 48%的文章使用PRO报告部分晚期不良事件,如UCLA-PCI、FACT-G和P、EORTC QLQ-C30+PR25,但无明确的「首选」工具。

临床怎么用

  • 建议在根治性放疗前、中、后纳入PRO评估,以全面捕捉患者体验。
  • 支持基于早期毒性严重程度开发晚期效应的预测模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This review aimed to determine the clinician and patient reported outcome (PRO) instruments currently usedin randomized controlled trials (RCTs) of radical radiation therapy for nonmetastatic prostate cancer to report acute and late adverse events (AEs), review the quality of methodology and PRO reporting, and report the prevalence of acute and late AEs. METHODS AND MATERIALS: The MEDLINE, EMBASE, and Cochrane databases were searched between April and August 2014 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. Identified reports were reviewed according to the PRO Consolidated Standards of Reporting Trials (CONSORT) guidelines and the Cochrane Risk of Bias tool. In all, 1149 records were screened, and 21 articles were included in the final review. RESULTS: We determined the acute and late AEs for 9040 patients enrolled in 15 different RCTs. Only clinician reported instruments were used to report acute AEs <3 months (eg, Radiation Therapy Oncology Group [RTOG] and Common Terminology Criteria for Adverse Events [CTCAE]). For late clinician reporting, the Late Effects on Normal Tissues-Subjective, Objective, Management and Analytic scale and RTOG were used and were often augmented with additional items to provide comprehensive coverage of sexual functioning and anorectal symptoms. Some late AEs were reported (48% articles) using PROs (eg, ULCA-PCI [University of California, Los Angeles Prostate Cancer Index], FACT-G and P [Functional Assessment of Cancer Therapy General & Prostate Module], EORTC QLQC-30 + PR25 [European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire & Prostate Module]); however, a definitive "preferred" instrument was not evident. DISCUSSION: Our findings are at odds with recent movements toward including patient voices in reporting of AEs and patient engagement in clinical research. We recommend including PRO to evaluate radical radiation therapy before, during, and after the treatment to fully capture patient experiences, and we support the development of predictive models for late effects based on the severity of early toxicity. CONCLUSION: Patient reporting of acute and late AEs is underrepresented in radiation therapy trials. We recommend working toward a consistent approach to PRO assessment of radiation therapy-related AEs.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Holch P, Henry AM, Davidson S, et al. Acute and Late Adverse Events Associated With Radical Radiation Therapy Prostate Cancer Treatment: A Systematic Review of Clinician and Patient Toxicity Reporting in Randomized Controlled Trials. Int J Radiat Oncol Biol Phys. 2016. PMID: 28126299. doi:10.1016/j.ijrobp.2016.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。